Table 2.
The comparison of assessed parameters (qualitative variables) with the ranges of BMI (WHO criteria) values.
| Variables | BMI | p-Value * | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| <18.5 n = 12 |
18.5–24.9 n = 203 |
25.0–29.9 n = 264 |
≥30 n = 296 |
|||||||
| n | % | n | % | n | % | n | % | |||
| Sex | M | 4 | 33.3 | 130 | 64.0 | 183 | 69.3 | 205 | 69.3 | 0.041 |
| NRS | <3 | 10 | 83.3 | 189 | 93.1 | 253 | 95.8 | 290 | 98.0 | 0.009 |
| ≥3 | 2 | 16.7 | 14 | 6.9 | 11 | 4.2 | 6 | 2.0 | ||
| HF phenotype | HFpEF | 3 | 25.0 | 49 | 24.1 | 66 | 25.0 | 100 | 33.8 | 0.23 |
| HFmrEF | 2 | 16.7 | 24 | 11.8 | 37 | 14.0 | 30 | 10.1 | ||
| HFrEF | 5 | 41.7 | 113 | 55.7 | 145 | 54.9 | 149 | 50.3 | ||
| No information | 2 | 16.7 | 17 | 8.4 | 16 | 6.1 | 17 | 5.7 | ||
| NYHA | 1 | 2 | 20.0 | 25 | 13.6 | 27 | 10.8 | 20 | 7.1 | 0.26 |
| 2 | 4 | 40.0 | 62 | 33.7 | 95 | 37.8 | 100 | 35.6 | ||
| 3 | 4 | 40.0 | 47 | 25.5 | 69 | 27.5 | 88 | 31.3 | ||
| 4 | 227 | 23.9 | 50 | 27.2 | 60 | 23.9 | 73 | 26.0 | ||
| CKD | Yes | 5 | 41.7 | 72 | 35.5 | 91 | 34.5 | 129 | 43.6 | 0.11 |
| MI | Yes | 3 | 25.0 | 72 | 35.5 | 80 | 30.3 | 78 | 26.4 | 0.18 |
| Type of MI | No | 9 | 75.0 | 131 | 64.5 | 184 | 69.7 | 218 | 73.6 | 0.53 |
| STEMI | 1 | 8.3 | 16 | 7.9 | 18 | 6.8 | 23 | 7.8 | ||
| NSTEMI | 2 | 16.7 | 50 | 24.6 | 53 | 20.1 | 51 | 17.2 | ||
| No information | - | - | 6 | 3.0 | 9 | 3.4 | 4 | 1.4 | ||
| HT | Yes | 9 | 75.0 | 118 | 58.1 | 197 | 74.6 | 239 | 80.7 | <0.001 |
| DM | Yes | 1 | 8.3 | 48 | 23.6 | 123 | 46.6 | 171 | 57.8 | <0.001 |
| CS | Yes | 1 | 8.3 | 25 | 12.3 | 37 | 14.0 | 37 | 12.5 | 0.89 |
| LDL | <55 mg/dL | - | - | 17 | 8.9 | 40 | 15.6 | 48 | 17.1 | 0.09 |
| 55 to <70 mg/dL | - | - | 17 | 8.9 | 40 | 15.6 | 48 | 17.1 | ||
| 70 to <100 mg/dL | 2 | 20.0 | 27 | 14.2 | 42 | 16.3 | 50 | 17.8 | ||
| 100 to <116 mg/dL | 3 | 30.0 | 22 | 11.6 | 26 | 10.1 | 34 | 12.1 | ||
| 116 to <190 mg/dL | 1 | 10.0 | 41 | 21.6 | 56 | 21.8 | 49 | 17.4 | ||
| more than 190 mg/dL | 6 | 3.2 | 2 | 0.8 | 1 | 0.4 | ||||
| LDL | ≥70 | 8 | 80.0 | 146 | 76.8 | 175 | 68.1 | 183 | 65.1 | 0.44 |
| TG | <135 | 8 | 72.7 | 147 | 75.8 | 202 | 78.6 | 170 | 60.1 | <0.001 |
| 135–200 | 1 | 9.1 | 34 | 17.5 | 36 | 14.0 | 74 | 26.1 | ||
| >200 | 2 | 18.2 | 13 | 6.7 | 19 | 7.4 | 39 | 13.8 | ||
| HDL | <40 | 5 | 50.0 | 76 | 40.0 | 119 | 46.1 | 178 | 62.9 | <0.001 |
| >40 | 5 | 50.0 | 114 | 60.0 | 139 | 53.9 | 105 | 37.1 | ||
Abbreviations: n, number of participants; M, males; p, level of significance; BMI, body mass index; NRS, nutritional risk screening; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFmrEF, heart failure with mid-range ejection fraction; HFrEF, heart failure with reduced ejection fraction; NYHA, New York Heart Association classification; CKD, chronic kidney disease; MI, myocardial infarction; STEMI, ST-elevation myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; HT, arterial hypertension; DM, diabetes mellitus; CS, cerebral stroke; LDL, low-density lipoprotein; TG, triglycerides; HDL, high-density lipoprotein; * χ2 test.